We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.18%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.45B
AUM Growth
+$67.8M
Cap. Flow
-$174M
Cap. Flow %
-5.03%
Top 10 Hldgs %
43.57%
Holding
114
New
15
Increased
22
Reduced
33
Closed
19

Top Buys

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$110M
2
AKRO
Akero Therapeutics
AKRO
+$64.9M
3
VIR icon
Vir Biotechnology
VIR
+$45.6M
4
MDT icon
Medtronic
MDT
+$40.2M
5
VRNA
Verona Pharma
VRNA
+$35.5M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$142M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$137M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$94.1M
4
SNY icon
Sanofi
SNY
+$41.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.57%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
51
Axsome Therapeutics
AXSM
$11.7B
$19.5M 0.56%
+271,493
New +$20M
SLDB icon
52
Solid Biosciences
SLDB
$794M
$18.3M 0.53%
3,495,933
– –
ATXS
53
DELISTED
Astria Therapeutics
ATXS
$18.2M 0.53%
2,189,462
– –
AORT icon
54
Artivion
AORT
$1.34B
$16M 0.46%
931,352
-154,508
-14% -$2.28M
BMEA icon
55
Biomea Fusion
BMEA
$89.7M
$15.7M 0.46%
716,441
+391,441
+120% +$12.3M
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.6M 0.45%
+245,800
New +$15.3M
MIRM icon
57
Mirum Pharmaceuticals
MIRM
$6.55B
$15.6M 0.45%
601,566
– –
TCMD icon
58
Tactile Systems Technology
TCMD
$617M
$15M 0.43%
602,377
-37,500
-6% -$779K
OBIO icon
59
Orchestra BioMed
OBIO
$228M
$14.4M 0.42%
2,052,868
-225,358
-10% -$3.42M
LONA
60
LeonaBio Inc
LONA
$65.3M
$14.2M 0.41%
479,728
– –
AXGN icon
61
Axogen
AXGN
$2.23B
$13.4M 0.39%
1,464,822
+55,031
+4% +$513K
FUSN
62
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$12.8M 0.37%
2,751,395
-8,541
-0.3% -$36.9K
PRTA icon
63
Prothena Corp
PRTA
$448M
$12.6M 0.36%
184,615
-53,031
-22% -$3.42M
CMAX
64
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$11.9M 0.34%
127,247
+8,046
+7% +$709K
SLNO
65
DELISTED
Soleno Therapeutics
SLNO
$9.47M 0.27%
+2,207,753
New +$9.49M
NBIX icon
66
Neurocrine Biosciences
NBIX
$18.2B
$9.43M 0.27%
100,050
– –
TERN
67
PUT
DELISTED
Terns Pharmaceuticals
TERN
$9.41M 0.27%
+1,075,000
New +$12.5M
SRPT icon
68
Sarepta Therapeutics
SRPT
$1.65B
$9.28M 0.27%
81,074
-179,784
-69% -$23.2M
BHVN icon
69
Biohaven
BHVN
$2.01B
$7.67M 0.22%
+320,820
New +$5.52M
VKTX icon
70
Viking Therapeutics
VKTX
$3.86B
$7.15M 0.21%
441,147
-430,600
-49% -$9.02M
XFOR icon
71
X4 Pharmaceuticals
XFOR
$375M
$6.88M 0.2%
118,182
-33,333
-22% -$1.71M
ISEE
72
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.61M 0.19%
168,000
-332,000
-66% -$11.7M
LABP
73
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$6.26M 0.18%
1,486,991
-1
-0% -$3
TYRA icon
74
Tyra Biosciences
TYRA
$1.85B
$6.13M 0.18%
360,000
-134,403
-27% -$1.95M
NBTX
75
Nanobiotix
NBTX
$1.95B
$5.37M 0.16%
1,059,800
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Perceptive Advisors held 114 positions worth $3.45B, up 2% from $3.39B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $174M in Q2 2023, closing 19 positions and reducing 33 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Medtronic worth $41.1M.

  • Perceptive Advisors's largest Q2 2023 buy was Medtronic: 467,000 shares worth $41.1M.
  • Perceptive Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2023, an estimated $110M increase.
  • Perceptive Advisors's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $142M.
  • Perceptive Advisors fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $137M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q2 2023.
  • Perceptive Advisors opened 15 new positions and closed 19 in Q2 2023.
  • Perceptive Advisors's portfolio value rose 2% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.